Company Profile
Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase III clinical trial for use in treatment of diabetic foot ulcers.
Its portfolio also includes ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial, ENERGI-F711, a burn cream, ENERGI-F703VLU, a gel that treats venous leg ulcers, ENERGI-F703EB, a topical cream for treating wounds in hereditary epidermolysis bullosa, ENERGI-F702 to treat metabolic diseases, ENERGI-F704 for the treatment of inflammatory bowel disease, ENERGI-F708 for asthma treatment, ENERGI-F705 for Parkinson's disease control, ENERGI-F707 for the treatment of mitochondria deficiency, ENERGI-F706 to treat cachexia, ENERGI-F709, a vaccine adjuvant, and ENERGI-F710 for blood phosphate control, as well as scientific products, including western blot, cell culture supplement, protein isolation, protein quantification, dyes, and buffer solutions. Energenesis Biomedical CO.,LTD. was founded in 2012 and is based in Taipei, Taiwan.